v3.26.1
Equity Investments (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 07, 2023
$ / shares
shares
Jun. 30, 2026
USD ($)
Apr. 30, 2024
USD ($)
shares
Apr. 30, 2022
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
May 31, 2021
USD ($)
shares
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Schedule of Equity Method Investments [Line Items]                      
Mark-to-market gain (loss) on equity investments             $ 45,868,000 $ 4,579,000 $ 32,381,000 $ (8,516,000)  
Structure Therapeutics                      
Schedule of Equity Method Investments [Line Items]                      
Mark-to-market gain (loss) on equity investments                 1,050,000    
Proceeds from disposal of shares                 20,334,000    
Series B Preferred Stock | Structure Therapeutics                      
Schedule of Equity Method Investments [Line Items]                      
Conversion ratio 1                    
Nimbus Therapeutics, LLC                      
Schedule of Equity Method Investments [Line Items]                      
Non-marketable equity security   $ 2,436,000         2,436,000   2,436,000   $ 2,436,000
Ajax Therapeutics, Inc                      
Schedule of Equity Method Investments [Line Items]                      
Non-marketable equity security   0         0   0   4,498,000
Proceeds from equity investment   57,180                  
Proceeds from equity stake in Ajax   47,180,000                  
Collaboration milestone payment   10,000                  
Mark-to-market gain (loss) on equity investments             42,144,000        
Ajax Therapeutics, Inc | Series B Preferred Stock                      
Schedule of Equity Method Investments [Line Items]                      
Number of preferred shares purchased (in shares) | shares           631,377          
Cash payments to purchase of shares           $ 1,700,000          
Ajax Therapeutics, Inc | Series C Preferred Stock                      
Schedule of Equity Method Investments [Line Items]                      
Number of preferred shares purchased (in shares) | shares     1,416,450                
Cash payments to purchase of shares     $ 3,000,000                
Structure Therapeutics                      
Schedule of Equity Method Investments [Line Items]                      
Mark-to-market gain (loss) on equity investments             3,725,000 $ 4,579,000 (10,813,000) $ (8,516,000)  
Marketable securities   $ 36,544,000         $ 36,544,000   $ 36,544,000   $ 66,641,000
Structure Therapeutics | Series B Preferred Stock                      
Schedule of Equity Method Investments [Line Items]                      
Number of preferred shares purchased (in shares) | shares       148,210 494,035            
Cash payments to purchase of shares       $ 600,000 $ 2,000,000            
Structure Therapeutics | ADR                      
Schedule of Equity Method Investments [Line Items]                      
Number of shares purchased (in shares) | shares 275,000                    
Purchase price (in USD per share) | $ / shares $ 15.00                    
Stock split, conversion ratio 3